Since patients received daily dosing of both AZD2171 and 250 mggefitinib, we also included four advanced NSCLC patients receiving 250 mggefitinib monotherapy to distinguish between any effects of VEGFR and EGFRinhibition. This evidence concerns the gene KDR and non-small cell lung carcinoma.